Categories
Anticancer Drugs Oncology Palonosetron Pharmacology Physiotherapy

Palonosetron and Highly Emetogenic Chemotherapy

In this article we will discuss Palonosetron and Highly Emetogenic Chemotherapy

In this article, we will discuss Palonosetron and Highly Emetogenic Chemotherapy. So, let’s get started.

Palonosetron and Highly Emetogenic Chemotherapy

A double-blind, dose-ranging trial evaluated the efficacy of a single intravenous dose of
palonosetron HCl from 0.3 to 90 mcg/kg (equivalent to < 0.1 mg to 6 mg fixed dose) in 161 chemotherapy-naïve adult cancer patients receiving highly-emetogenic chemotherapy (either cisplatin ≥ 70 mg/m² or cyclophosphamide > 1,100 mg/m²).
Concomitant corticosteroids were not administered prophylactically. Analysis of data from this trial indicates that 0.25 mg is the lowest effective dose in preventing acute nausea and vomiting induced by highly emetogenic chemotherapy.

A double-blind trial involving 667 patients compared a single intravenous dose of
palonosetron HCl with a single intravenous dose of ondansetron (Study 3) given 30
minutes prior to highly emetogenic chemotherapy including cisplatin ≥ 60 mg/m², cyclophosphamide > 1,500 mg/m², and dacarbazine. Corticosteroids were co-
administered prophylactically before chemotherapy in 67% of patients. Of the 667 patients, 51% were women, 60% White, and 59% naïve to previous chemotherapy. The
mean age was 52 years.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.